Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salvage BCL2i Plus CLAG-M in Relapsed or Refractory Acute Myeloid Leukemia
NCT06660368Phase 2Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Nov 2024
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of venetoclax in acute myeloid leukemia (AML) (2 arms), sponsored by Moffitt Cancer Center. Primary endpoint: Measurable Residual Disease-Negative Remission Rate at 18 months. Started Nov 2024; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06660368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06660368.